Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: J Neurooncol. 2016 Jul 14;130(1):31–42. doi: 10.1007/s11060-016-2217-7

Fig. 3.

Fig. 3

Percent of record complete by year for required site specific factors (SSF) 4–6 for (a) diffuse astrocytoma, (b) anaplastic astrocytoma, (c) glioblastoma, (d) oligodendroglioma, (e) anaplastic oligodendroglioma, and (f) oligoastrocytic tumors, SEER 2010–2012